{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:39:59Z","timestamp":1792269599405,"version":"4.4.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have become one of the standard therapeutic regimens for advanced lung cancer. However, the risk of infection-related complications induced by ICIs, particularly reactivation of tuberculosis, has attracted increasing clinical attention. Herein, we report a 72-year-old male patient with squamous cell carcinoma of the lung who developed reactivation of latent tuberculosis infection (LTBI) approximately 13 months after sequential PD-1 inhibitor therapy. During anti-tuberculosis treatment, the patient was further diagnosed with a second primary ascending colon adenocarcinoma. Combined with this index case and 26 previously published cases of ICI-associated tuberculosis infection identified via literature review, we explore the potential correlation between PD-1\/PD-L1 inhibitor therapy and tuberculosis reactivation, as well as corresponding clinical manifestations and comprehensive management strategies. Our findings suggest that clinicians should attach great importance to tuberculosis screening and continuous monitoring throughout the entire course of ICI treatment. For complex patients concurrently complicated with second primary malignancies and infectious diseases, a multidisciplinary team (MDT) approach should be adopted to formulate individualized treatment regimens.<\/jats:p>","DOI":"10.3389\/fonc.2026.1848651","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:15:12Z","timestamp":1788412512000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Lung squamous cell carcinoma complicated with immune checkpoint inhibitor-associated active tuberculosis: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiufang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second People\u2019s Hospital of Quzhou","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Rehabilitative, The Second People\u2019s Hospital of Quzhou","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second People\u2019s Hospital of Quzhou","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second People\u2019s Hospital of Quzhou","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02512-2021","article-title":"The paradox of immune checkpoint inhibition re-activating tuberculosis","volume":"60","author":"Ahmed","year":"2022","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02726-1","article-title":"Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review","volume":"70","author":"Suliman","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.024","article-title":"Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: a proof-of-concept, phase 2 trial","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2015.1125017","article-title":"Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma","volume":"55","author":"Lee","year":"2016","journal-title":"Acta Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.03.012","article-title":"Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma","volume":"12","author":"Chu","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2018.06.016","article-title":"Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents","volume":"25","author":"Takata","year":"2019","journal-title":"J Infect Chemother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s40425-019-0717-7","article-title":"Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations","volume":"7","author":"Anastasopoulou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/1759-7714.13821","article-title":"Long-term remission of small cell lung cancer after reactivation of tuberculosis following immune-checkpoint blockade: a case report","volume":"12","author":"Sirgiovanni","year":"2021","journal-title":"Thorac Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0061","article-title":"Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report","volume":"12","author":"Kato","year":"2020","journal-title":"Immunotherapy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1186\/s12879-021-06845-7","article-title":"Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report","volume":"21","author":"Lau","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6002-20","article-title":"Readministration of pembrolizumab after treatment of tuberculosis activated by initial pembrolizumab therapy","volume":"60","author":"Murakami","year":"2021","journal-title":"Intern Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100319","article-title":"Complete remission after immunotherapy-induced abdominal tuberculosis in a patient with advanced NSCLC treated with pembrolizumab: a case report","volume":"3","author":"Riudavets","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S178246","article-title":"Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report","volume":"11","author":"He","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1433877","article-title":"Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer","volume":"57","author":"Jensen","year":"2018","journal-title":"Acta Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_410_22","article-title":"A rare case of miliary tuberculosis in a patient with NSCLC receiving PD1 inhibitor therapy, mimicking autoimmune pneumonitis","volume":"19","author":"Nikola","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcy243","article-title":"Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment","volume":"112","author":"Tsai","year":"2019","journal-title":"QJM"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00659","article-title":"Tuberculosis infection in a patient treated with nivolumab for non-small cell lung cancer: case report and literature review","volume":"9","author":"Van","year":"2019","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1250LE","article-title":"Implications of tuberculosis reactivation after immune checkpoint inhibition","volume":"198","author":"Elkington","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162190","article-title":"Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review","volume":"14","author":"Lin","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1301562","DOI":"10.1155\/2018\/1301562","article-title":"Significant neutrophilic emperipolesis in squamous cell carcinoma","author":"Tetikkurt","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/cco-23-153","article-title":"A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment","volume":"13","author":"Hirano","year":"2024","journal-title":"Chin Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i28.6938","article-title":"Pulmonary reversed halo cycles and consolidations after immunotherapy: a case report","volume":"11","author":"Suo","year":"2023","journal-title":"World J Clin cases"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2016.10.001","article-title":"The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis","volume":"101","author":"Shen","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/srep38362","article-title":"PD-1\/PD-L pathway inhibits M.tb-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis","volume":"6","author":"Shen","year":"2016","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019864","article-title":"T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection","volume":"6","author":"Tousif","year":"2011","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005667","article-title":"CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease","volume":"12","author":"Sakai","year":"2016","journal-title":"PloS Pathog"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900116","article-title":"Prednisone for prevention of paradoxical tuberculosis-associated IRIS","volume":"380","author":"Jones","year":"2019","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1007394107","article-title":"Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis","volume":"107","author":"Lazar-Molnar","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-19","article-title":"Opportunistic infections in patients treated with immunotherapy for cancer","volume":"2","author":"Kyi","year":"2014","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1025","article-title":"Inflammatory and infectious syndromes associated with cancer immunotherapies","volume":"69","author":"Fishman","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01356-5","article-title":"Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials","volume":"41","author":"Li","year":"2023","journal-title":"Invest New Drugs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin Pharmacokinet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1848651\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:15:14Z","timestamp":1788412514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1848651\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":42,"alternative-id":["10.3389\/fonc.2026.1848651"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1848651","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1848651"}}